Table 3.
Treatment-related adverse events of all grades occurring in more than 15% of patients
| Events, n (%) | All patients (n = 35) | ||
|---|---|---|---|
| Any grade | Grade 1–2 | Grade 3 or higher | |
| Aspartate aminotransferase increased | 34 (97.1) | 24 (68.6) | 10 (28.6) |
| Alanine aminotransferase increased | 33 (94.3) | 26 (74.3) | 7 (20.0) |
| Hypoalbuminemia | 31 (88.6) | 31 (88.6) | 0 |
| Neutrophil count decreased | 29 (82.9) | 17 (48.6) | 12 (34.3) |
| Lymphocyte count decreased | 27 (77.1) | 14 (40.0) | 13 (37.1) |
| Anemia | 25 (71.4) | 23 (65.7) | 2 (5.7) |
| Platelet count decreased | 23 (65.7) | 15 (42.9) | 8 (22.9) |
| Blood bilirubin increased | 22 (62.9) | 19 (54.3) | 3 (8.6) |
| Proteinuria | 22 (62.9) | 22 (62.9) | 0 |
| Abdominal pain | 21 (60.0) | 21 (60.0) | 0 |
| White blood cell decreased | 20 (57.1) | 14 (40.0) | 6 (17.1) |
| Weight loss | 17 (48.6) | 17 (48.6) | 0 |
| Anorexia | 17 (48.6) | 17 (48.6) | 0 |
| Hyperglycemia | 16 (45.7) | 16 (45.7) | 0 |
| Hyponatremia | 15 (42.9) | 14 (40.0) | 1 (2.9) |
| Hyperuricemia | 15 (42.9) | 15 (42.9) | 0 |
| Hypokalemia | 14 (40.0) | 12 (34.3) | 2 (5.7) |
| Rash | 14 (40.0) | 12 (34.3) | 2 (5.7) |
| Hypertension | 14 (40.0) | 9 (25.7) | 5 (14.3) |
| Hand-foot syndrome | 13 (37.1) | 10 (28.6) | 3 (8.6) |
| RCCEP | 13 (37.1) | 12 (34.3) | 1 (2.9) |
| Diarrhea | 13 (37.1) | 12 (34.3) | 1 (2.9) |
| Vomiting | 12 (34.3) | 12 (34.3) | 0 |
| Fatigue | 11 (31.4) | 11 (31.4) | 0 |
| Hematuria | 11 (31.4) | 11 (31.4) | 0 |
| Upper respiratory infection | 9 (25.7) | 9 (25.7) | 0 |
| Gingival hemorrhage | 9 (25.7) | 9 (25.7) | 0 |
| Fever | 8 (22.9) | 8 (22.9) | 0 |
| Oral mucositis | 8 (22.9) | 8 (22.9) | 0 |
| Gingivitis | 8 (22.9) | 8 (22.9) | 0 |
| Ascites | 7 (20.0) | 7 (20.0) | 0 |
| Epistaxis | 7 (20.0) | 7 (20.0) | 0 |
| Cough | 6 (17.1) | 6 (17.1) | 0 |
| Headache | 6 (17.1) | 6 (17.1) | 0 |
RCCEP reactive cutaneous capillary endothelial proliferation